Report Faults Pay-for-Delay Agreements for Some High Drug Prices
The Federal Trade Commission (FTC) has issued a report criticizing the drug industry for using so-called “pay-for-delay” agreements to keep drug prices high. “The delays in competition resulting from these agreements can be significant,” stated the FTC in a release announcing the results of the final report.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.